PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of CRVO's 100.00%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-502.30%
Higher Other Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
-57.89%
Less than half of CRVO's 28.85%. David Dodd sees a more disciplined short-term liability approach.
43.72%
Higher Long-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.72%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
20.19%
50-75% of CRVO's 28.85%. Bruce Berkowitz notes a lower yoy liability increase.
No Data
No Data available this quarter, please select a different quarter.
-1.97%
≥ 1.5x CRVO's -0.34%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
-86.83%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-20.70%
0.5-0.75x CRVO's -28.85%. Martin Whitman is wary of lagging equity growth vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.72%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
45.18%
Higher Net Debt Growth compared to CRVO's zero value, indicating worse performance.